A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">Number (%) of patients</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Alive</td><td align="center">58 (29.7)</td></tr><tr><td align="left">Dead</td><td align="center">126 (64.6)</td></tr><tr><td align="left">Lost to followup</td><td align="center">4 (2.1)</td></tr><tr><td align="left">Missing status reports</td><td align="center">7 (3.6)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>The percentage is calculated out of 195, the total number of patients in the survey’s cohort.<br/></td></tr></table>

Chemotherapy Research and Practice

tab4

Table 4

Table 4: A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 

Table 4 | A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 